OTSUKA PHARMACEUTICAL DEVELOPMENT & COMMERCIALIZATION, INC.
A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder (PTSD)
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2021-12-08
- Target Recruit Count
- 336
- Registration Number
- NCT03033069
- Locations
- πΊπΈ
Investigational Site, Everett, Washington, United States
An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2024-07-05
- Target Recruit Count
- 157
- Registration Number
- NCT02970929
- Locations
- πΊπΈ
CNRI-Los Angeles, LLC, Pico Rivera, California, United States
πΊπΈAtlanta Center for Medical Research, Atlanta, Georgia, United States
πΊπΈUCSD Medical Center UCSD Department of Psychiatry, San Diego, California, United States
A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-07-05
- Target Recruit Count
- 245
- Registration Number
- NCT02969382
- Locations
- π·π΄
Spitalul Clinic de Neuropsihiatrie Craiova, Craiova, Romania
πΊπΈAtlanta Center for Medical Research, Atlanta, Georgia, United States
πΊπΈCalifornia Neuropsychopharmacology Clinical Research Institute-LA, LLC(CNRI- LA, LLC), Pico Rivera, California, United States
A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis
- Conditions
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-07-05
- Target Recruit Count
- 39
- Registration Number
- NCT02969369
- Locations
- πΊπΈ
Keck School of Medicine of USC/ University of Southern California, Los Angeles, California, United States
πΊπΈUniversity of Miami, Dept. of Neurology, Miami, Florida, United States
πΊπΈThe Emory Clinic, Atlanta, Georgia, United States
Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2018-01-12
- Target Recruit Count
- 22
- Registration Number
- NCT02968121
- Locations
- πΊπΈ
CNRI, San Diego, California, United States
πΊπΈCollaborative Neuro Science (CNS), Garden Grove, California, United States
Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
- Conditions
- Interventions
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2023-01-03
- Target Recruit Count
- 91
- Registration Number
- NCT02964273
A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2022-02-18
- Target Recruit Count
- 16
- Registration Number
- NCT02827513
Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System
- Conditions
- Interventions
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2018-05-23
- Target Recruit Count
- 49
- Registration Number
- NCT02722967
A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 213
- Registration Number
- NCT02573350
- Locations
- πͺπͺ
Tartu University Lung Hospital, Tartu, Estonia
π°π·Asan Medical Center, Seoul, Korea, Republic of
π°π·Younsei University Medical Center, Seoul, Korea, Republic of
Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2021-11-11
- Target Recruit Count
- 85
- Registration Number
- NCT02547428